drugset / Trial / NCT04202952
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects
Timeline
- Start
- 2020-07-06
- Primary completion
- 2020-08-27
- Completion
- 2020-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HEC110114 | Unknown | 600 mg | Oral |
| Subject | HEC110114 | Unknown | 800 mg | Oral |
| Subject | HEC110114 | Unknown | 1200 mg | Oral |
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |